Ryan McDonald

The FDA plans to accelerate its review of IK-930, an investigational drug, for the treatment of patients with unresectable NF2-deficient malignant pleural mesothelioma, a rare cancer.

Treatment with the novel CAR-T cell therapy was associated with favorable efficacy and safety results in a group of patients with follicular lymphoma, including a few with Waldenstrom macroglobulinemia, according to findings from a study presented at a recent medical conference.

Watch Dr. Keerthi Gogineni, from Emory University School of Medicine, discuss the management of triple-negative disease, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Treatment with an experimental drug delivered through a minimally invasive procedure may show promise in patients with liver cancer that cannot be treated with surgery.

The FDA approval of the first poly (adenosine diphosphate-ribose) polymerase, or PARP, inhibitor in the 2010s has drastically changed how patients with gynecologic cancers are treated.

Sierra Oncology noted in a company-issued press release that if momelotinib is approved by the FDA that they anticipate making the drug available to patients with myelofibrosis next year.

Watch Dr. Andrew Z. Wang, from UT Southwestern Medical Center, discuss approaches to radiation for local disease, during the CURE Educated Patient Prostate Cancer Summit.

After more than two years of follow-up, patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from treatment with Keytruda and chemoradiation.

Watch Dr. Ganesh V. Raj, from UT Southwestern Medical Center, discuss surgery for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

An analysis of more than 25,000 patients with one of the more than 20 common cancers identified that even though telehealth use for cancer care increased during the COVID-19 pandemic, certain people were less likely to benefit from the easy access to care.

The aim of the early-stage trial is to identify the safety of the experimental drug as either a single-agent therapy as well as in combination with Keytruda in adults with multiple solid tumors.

Watch Dr. Bart Scott, from Fred Hutchinson Cancer Center, discuss current treatment options, during the CURE Educated Patient MPN Summit.

Watch Dr. Aaron Gerds, from Cleveland Clinic Taussig Cancer Institute, discuss approaches to diagnosing and assessing symptoms, during the CURE Educated Patient MPN Summit.

From Grammy-award winning artist Sheryl Crow discussing her breast cancer journey to a 4-year-old reconnecting with their favorite nurse, here’s what’s happening in the cancer space this week.

Findings from an early-stage trial assessing Talzenna in combination with a novel drug, known as ZEN-3694, have led the manufacturer to initiate a later-stage study in patients with triple-negative breast cancer.

The primary objective of the early-stage trial is to determine the maximum tolerated dose of the novel drug in a group of patients with recurrent and/or refractory solid tumors.

The FDA’s extended approval of Lynparza, according to an expert, gives patients with early-stage, high-risk breast cancer a reasonable treatment option to consider.

Treatment with an investigational cancer vaccine plus Tecentriq was associated with positive outcomes in patients with heavily pre-treated advanced cervical cancer, according to findings from an interim analysis of a phase 2 trial.

The manufacturers of the drug plan to resubmit the request for the FDA to approve the regimen sometime this summer.

Researchers are set to launch a new study to examine the feasibility of using an in-home virtual reality-guided mindfulness program to mitigate the effects of chronic cancer-related pain in patients and cancer survivors.

The priority review means that the FDA plans to speed up its review of Imfinzi combined with chemotherapy in patients with advanced or metastatic biliary tract cancer.

Watch Dr. Saby George, from Roswell Park Comprehensive Cancer Center, discuss treatment with the combination of immunotherapies, during the CURE Educated Patient Kidney Cancer Summit.

For the first time in three years, CURE® welcomed 500 attendees in person and hundreds more virtually to honor the 2022 Extraordinary Healer® award recipient.

The drug, known as BDTX-1535, is being investigated in patients with glioblastoma that harbors EGFR alterations and non-small cell lung cancer that harbors EGFR mutations of intrinsic or acquired resistance and disease that has failed standard treatment.

Watch Dr. Naomi Haas, from Abramson Cancer Center, discuss adjuvant therapy options, during the CURE Educated Patient Kidney Cancer Summit.

Once a recommended dose of the drug is determined, the study investigators will review the efficacy and safety associated with this treatment across a variety of patients with bladder and liver cancer, as well other solid tumors.

The plan to launch the phase 1 trial to evaluate the safety and efficacy of combining the CAR-T cell therapy and oncolytic virus in patients with recurrent glioblastoma, a type of brain cancer, is supported by interim data from two ongoing trials.

The primary focus of the trial is to evaluate the incidence of treatment-emergent and serious side effects in patients receiving either the novel drug alone or in combination with Keytruda.